Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Genentech, Dako collaborate on diagnostic tests for stomach cancer
September 2009
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.Genentech Inc. announced in August that it has signed an agreement with Dako, a global provider of cancer diagnostic solutions based in Denmark, to collaborate on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for Herceptin (trastuzumab) in patients with advanced HER2-positive stomach (gastric) cancer. Based on the Herceptin ToGA Phase III study results, which were presented on May 31 at the American Society for Clinical Oncology's annual meeting in Orlando, Fla., Genentech may seek regulatory approvals in the United States for the use of Herceptin in advanced HER2-positive stomach cancer. Financial terms of the agreement were not disclosed.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.